IDXX Valuation

IDEXX Laboratories Inc

Add to Watchlist

Advanced Chart

650.060

+25.87(4.145%)1D

Overview
Forecast
Valuation
Earnings

IDXX Relative Valuation

IDXX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IDXX is overvalued; if below, it's undervalued.

Historical Valuation

IDEXX Laboratories Inc (IDXX) is now in the Fair zone, suggesting that its current forward PE ratio of 47.86 is considered Fairly compared with the five-year average of 51.60. The fair price of IDEXX Laboratories Inc (IDXX) is between 489.03 to 750.57 according to relative valuation methord.

Relative Value

Fair Zone

489.03-750.57

Current Price：624.19

Fair

47.86

Trailing

Forward

34.13

EV/EBITDA

IDEXX Laboratories Inc. (IDXX) has a current EV/EBITDA of 34.13. The 5-year average EV/EBITDA is 36.00. The thresholds are as follows: Strongly Undervalued below 18.86, Undervalued between 18.86 and 27.43, Fairly Valued between 44.57 and 27.43, Overvalued between 44.57 and 53.14, and Strongly Overvalued above 53.14. The current Forward EV/EBITDA of 34.13 falls within the Historic Trend Line -Fairly Valued range.

37.83

EV/EBIT

IDEXX Laboratories Inc. (IDXX) has a current EV/EBIT of 37.83. The 5-year average EV/EBIT is 40.34. The thresholds are as follows: Strongly Undervalued below 20.38, Undervalued between 20.38 and 30.36, Fairly Valued between 50.32 and 30.36, Overvalued between 50.32 and 60.30, and Strongly Overvalued above 60.30. The current Forward EV/EBIT of 37.83 falls within the Historic Trend Line -Fairly Valued range.

11.75

IDEXX Laboratories Inc. (IDXX) has a current PS of 11.75. The 5-year average PS is 11.34. The thresholds are as follows: Strongly Undervalued below 6.36, Undervalued between 6.36 and 8.85, Fairly Valued between 13.84 and 8.85, Overvalued between 13.84 and 16.33, and Strongly Overvalued above 16.33. The current Forward PS of 11.75 falls within the Historic Trend Line -Fairly Valued range.

41.50

P/OCF

IDEXX Laboratories Inc. (IDXX) has a current P/OCF of 41.50. The 5-year average P/OCF is 46.09. The thresholds are as follows: Strongly Undervalued below 21.15, Undervalued between 21.15 and 33.62, Fairly Valued between 58.56 and 33.62, Overvalued between 58.56 and 71.03, and Strongly Overvalued above 71.03. The current Forward P/OCF of 41.50 falls within the Historic Trend Line -Fairly Valued range.

49.15

P/FCF

IDEXX Laboratories Inc. (IDXX) has a current P/FCF of 49.15. The 5-year average P/FCF is 54.79. The thresholds are as follows: Strongly Undervalued below 24.99, Undervalued between 24.99 and 39.89, Fairly Valued between 69.69 and 39.89, Overvalued between 69.69 and 84.58, and Strongly Overvalued above 84.58. The current Forward P/FCF of 49.15 falls within the Historic Trend Line -Fairly Valued range.

IDEXX Laboratories Inc (IDXX) has a current Price-to-Book (P/B) ratio of 34.41. Compared to its 3-year average P/B ratio of 37.81 , the current P/B ratio is approximately -9.01% higher. Relative to its 5-year average P/B ratio of 52.06, the current P/B ratio is about -33.91% higher. IDEXX Laboratories Inc (IDXX) has a Forward Free Cash Flow (FCF) yield of approximately 1.53%. Compared to its 3-year average FCF yield of 1.73%, the current FCF yield is approximately -11.86% lower. Relative to its 5-year average FCF yield of 1.58% , the current FCF yield is about -3.31% lower.

34.41

P/B

Median3y

37.81

Median5y

52.06

1.53

FCF Yield

Median3y

1.73

Median5y

1.58

Competitors Valuation Multiple

The average P/S ratio for IDXX's competitors is 6.24, providing a benchmark for relative valuation. IDEXX Laboratories Inc Corp (IDXX) exhibits a P/S ratio of 11.75, which is 88.08% above the industry average. Given its robust revenue growth of 10.55%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

IDXX.O

IDEXX Laboratories Inc

Edwards Lifesciences Corp

Becton Dickinson and Co

Agilent Technologies Inc

4.70

6.04%

32.38B

Performance Decomposition

Market capitalization of IDXX increased by 29.68% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 20.26 to 26.50.

The secondary factor is the Revenue Growth, contributed 10.55%to the performance.

Overall, the performance of IDXX in the past 1 year is driven by Margin Expansion. Which is more sustainable.

10.55%

1.00B → 1.11B

Revenue Growth

30.80%

20.26 → 26.50

Margin Expansion

-11.67%

59.76 → 52.78

P/E Change

29.68%